Western Diet Linked to Higher Colon Ca Relapse Rate

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

Patients with stage III colon cancer who have undergone surgery and chemotherapy with curative intent may have a higher risk of relapse and death if they follow a predominantly "Western" diet

ASCO—Patients with stage III colon cancer who have undergone surgery and chemotherapy with curative intent may have a higher risk of relapse and death if they follow a predominantly "Western" diet, Jeffrey Meyerhardt, MD, said at the 2007 American Society of Clinical Oncology annual meeting (abstract 4019).

"This is the first large prospective trial to look at how diet impacts colon cancer survivors, and while the results are preliminary, they are highly suggestive that diet may impact the outcome of these patients," said Dr. Meyerhardt, of Dana-Farber Cancer Institute.

The research involved 1,009 patients with stage III colon cancer who were participating in a randomized, phase III clinical trial of adjuvant chemotherapy. They recorded their dietary intake on questionnaires during and 6 months after chemotherapy, and were followed for a median of 5.3 years. Analysis of the questionnaires showed two dietary patterns: "prudent," characterized by high fruit, vegetable, poultry, and fish intake, and "Western," characterized by high intake of red meat, fat, and sweets.

Multivariate analysis found that patients in the highest quintile of Western diet had nearly a fourfold increase in risk of recurrence or death from any cause (disease-free survival), compared with those in the lowest quintile (HR 3.91, P < .0001). This diet was also associated with significantly lower overall recurrence-free survival and higher overall mortality. By contrast, the prudent diet pattern did not significantly influence cancer recurrence or mortality.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content